Pharmacokinetic/pharmacodynamic (PK/PD) Characteristics of Veliparib with and without Temozolomide in Patients with Hematological Malignancies

被引：0
|
作者：
Singh, Renu [1 ]
Gopalakrishnan, Mathangi [1 ]
Kiesel, Brian F. [2 ]
Greer, Jacqueline M. [3 ]
Karp, Judith E. [3 ]
Gojo, Ivana [3 ]
Gobburu, Jogarao [1 ]
Rudek, Michelle A. [3 ]
Beumer, Jan H. [2 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[3] Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-47
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [31] In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
    Xiao, Xia
    Sun, Jian
    Chen, Yi
    Huang, Rui-Juan
    Huang, Ting
    Qiao, Guilin Gary
    Zhou, Yu-Feng
    Liu, Ya-Hong
    BMC VETERINARY RESEARCH, 2015, 11
  • [32] METHADONE INFUSIONS - PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    MAX, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (02) : 211 - 211
  • [33] Pharmacokinetic/pharmacodynamic (PK/PD) modeling of captopril in healthy volunteers.
    Yi, SY
    Bae, KS
    Lim, HS
    Cho, JY
    Yu, KS
    Jang, IJ
    Shin, SG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P74 - P74
  • [34] Assessment of pharmacokinetic (PK) and pharmacodynamic (PD) interaction between warfarin and repaglinide
    Rosenberg, M
    Strange, P
    Cohen, A
    DIABETES, 1999, 48 : A356 - A356
  • [35] Translational pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of MetMAb
    Bender, B.
    Xiang, H.
    Reyes, A. E., II
    Damico, L. A.
    Merchant, M.
    Peterson, A.
    Forrest, W.
    Jumbe, N. L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 170 - 170
  • [36] POPULATION PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) MODELING OF TICARCILLIN-CLAVULANATE IN PEDIATRIC CF PATIENTS
    Zobell, J. T.
    Stockmann, C.
    Young, D. C.
    Cash, J.
    Sherwin, C.
    Spigarelli, M.
    Chatfield, B. A.
    Ampofo, K.
    PEDIATRIC PULMONOLOGY, 2011, : 311 - 312
  • [37] CLADRIBINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC POTENTIAL IN HEMATOLOGICAL MALIGNANCIES
    BRYSON, HM
    SORKIN, EM
    DRUGS, 1993, 46 (05) : 872 - 894
  • [38] Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run In Part of a Phase II Trial of the Orally Available MEK-Inhibitor MSC1936369 In Patients with Advanced Hematological Malignancies
    Ravandi, Farhad
    Pigneux, Arnaud
    Smith, Douglas
    Dombret, Herve
    Thomas, Xavier
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    DeAngelo, Daniel J.
    Pratz, Keith W.
    Asatiani, Ekaterine
    Gianella-Borradori, Athos
    Longerey, Blandine
    Harousseau, Jean-Luc
    BLOOD, 2010, 116 (21) : 1350 - 1350
  • [39] DEVELOPMENT OF A PHARMACOKINETIC (PK)/PHARMACODYNAMIC (PD) MODEL TO EVALUATE THE IMPACT OF PK VARIATION ON PD FOR EXTENDED RELEASE METOPROLOL FORMULATIONS
    Sharma, V. D.
    Trame, M. N.
    Schmidt, S.
    Fang, L. L.
    Lesko, L. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S9 - S9
  • [40] In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
    Xiao, Xia
    Lan, Weixuan
    Zhao, Yaqin
    Li, Ruichao
    Liu, Yuan
    Liu, Juan
    Wang, Zhiqiang
    FRONTIERS IN MICROBIOLOGY, 2021, 11
12345